prothymosin alpha is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-04-16. Where a claim depends on a specific study, the study is described rather than over-claimed.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography, which separates the peptide from closely related impurities and from truncated or oxidized variants. Mass spectrometry supplies the molecular mass and confirms the expected sequence length, while amino acid analysis can be used to check composition. Because the molecule has no chromophore beyond the peptide backbone, ultraviolet detection is typically performed at a low wavelength, where baseline interference from solvents and buffers is a practical concern. Water content and counter-ion content are often reported alongside purity.
Practical handling focuses on limiting adsorption and contamination. The peptide dissolves readily in water, and dilute solutions tend to adhere to plastic and glass surfaces, so an inert carrier protein or a defined buffer can reduce losses in laboratory work. Workers also record the counter-ion form, since an acetate or trifluoroacetate salt changes the mass balance of the weighed powder. Documentation of lot number, purity value, and storage history supports reproducibility when results from different laboratories are compared.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide, 28 residues | N-terminal fragment of prothymosin alpha |
| Molecular mass | About 3108 Da | Acetylated form |
| Isoelectric point | Near 4.2 | Acidic peptide |
| Appearance | White to off-white lyophilized powder | Common supplied form |
| Typical storage | -20 °C or below, dry | Solution stability is lower |
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Thymosin alpha-1 is a short peptide of 28 amino acid residues first described in the 1970s as a component of thymic extracts. Its N-terminal residue carries an acetyl group, and the sequence is highly conserved across mammalian species. The peptide is not encoded as a standalone gene product; it is released by proteolytic cleavage from the N-terminus of prothymosin alpha, a larger acidic nuclear protein. That precursor relationship places it within a broader family of thymic and immune-associated peptides that have been studied for decades.
The activity of this peptide is generally described as immunomodulatory rather than directly antimicrobial. Experimental work links it to signaling through certain Toll-like receptors on dendritic cells and to downstream maturation of antigen-presenting cells. Reported effects include expansion of T cell subsets, shifts in cytokine profiles, and increased natural killer cell activity. These observations come largely from cell culture and animal models, and the precise receptor-level events in humans remain incompletely characterized.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Storage recommendations center on low temperature, dryness, and protection from repeated freezing and thawing. The intact powder is commonly held at 20 degrees below zero Celsius or colder, while a working solution is divided into single-use aliquots to limit freeze-thaw cycles. Buffered saline or phosphate-buffered saline at neutral pH is frequently used as a diluent. Light sensitivity is not well documented, yet amber vials or foil wrapping are common practice for long-term storage of peptide stocks.
Identity and purity are assessed with a small set of standard peptide methods. Reversed-phase high-performance liquid chromatography separates the main peak from truncated or oxidized species, and its area percentage is the usual purity measure. Mass spectrometry confirms the observed molecular mass against the expected value, while amino acid analysis or peptide mapping checks composition and sequence. Specifications for research-grade material are often stated as 95 percent or higher, though the exact limit depends on the supplier and the intended use.
== History == UK-5099 (JXL001), the earlier MPC inhibitor from which suvomipic was derived, was first described in the scientific literature by 1975. Suvomipic is under development by Pelage Pharmaceuticals. In 2025, it was reported that lab work on the drug had been ongoing for almost a decade. It originated at the University of California, Los Angeles (UCLA), with Pelage Pharmaceuticals being founded and spun out of UCLA in 2018 by three scientists at the university. These academics included Bill Lowry, Heather Christofk, and Michael Jung. The chief medical officer (CMO) of the company is Qing Yu Christina Weng. Pelage Pharmaceuticals was named after the French word for "coat of fur" and "PP405" was named after the company and the 405 freeway that goes through Los Angeles. The first human clinical trials of suvomipic started in 2023 in Orange County.
Fabomotizole (INN), sold under the brand name Afobazole, is an anxiolytic drug launched in Russia in the early 2000s. It produces anxiolytic and neuroprotective effects without any sedative or muscle relaxant actions. Its mechanism of action remains poorly defined however, with GABAergic, NGF- and BDNF-release-promoting, MT1 receptor agonism, MT3 receptor antagonism, and sigma agonism suggested as potential mechanisms. Fabomotizole was shown to inhibit MAO-A reversibly and may potentially have some involvement with serotonin receptors. Clinical trials have shown fabomotizole to be well tolerated and reasonably effective for the treatment of anxiety. Experiments in mice have shown antimutagenic and antiteratogenic properties. Experiments in rats have shown beneficial effect in the model of ischemic stroke. Fabomotizole has found little clinical use outside Russia and has not been evaluated by the FDA.
Thiamine pyrophosphate (TPP), also called thiamine diphosphate (ThDP), participates as a coenzyme in metabolic reactions, including those in which polarity inversion takes place. Its synthesis is catalyzed by the enzyme thiamine diphosphokinase according to the reaction thiamine + ATP → TPP + AMP (EC 2.7.6.2). However, recent findings reveal that uridine 5′-triphosphate (UTP), rather than ATP, is the preferred substrate for TPP synthesis in cells, with TPK1 showing a ~10-fold higher affinity for UTP. TPP is a coenzyme for several enzymes that catalyze the transfer of two-carbon units and in particular the dehydrogenation (decarboxylation and subsequent conjugation with coenzyme A) of 2-oxoacids (alpha-keto acids). The mechanism of action of TPP as a coenzyme relies on its ability to form an ylide. Examples include:
"I believe that all the power of the supreme being is not enough to liberate that despicable country (Peru): only Bolívar, supported by force, can do it." It is also known that San Martín wanted the disputed territory of Upper Peru, administered since 1810 by the Viceroyalty of Peru, to be handed over to the United Provinces of the Río de la Plata, which, although it would be somewhat predictable on his part (because it was an Argentine) in the exercise of a realpolitik, on the other hand it would be a sign of anti-Peruvianism on his part in the face of vague promises that he made to warlords, like Andrés de Santa Cruz, over the territory. Given this, he was allegedly accused of being dishonest with his ambiguous promises that he gave to Peruvian politicians who supported his government, since the Protectorate of San Martín de facto controlled the Atacama Party and was also claiming part of the territories of the current La Paz and Pando. That ended up generating a climate of mistrust, where the praises and praise of the Peruvians to the Liberator would have been apparent, in the midst of hostilities towards the Argentine caudillo. In the secret session of the Peruvian Congress, on September 27, 1822, suspicion and fear were expressed that San Martín tried to seize the provinces of Upper Peru, Arequipa and Cuzco.
Sources: en.wikipedia.org
=== Diet === In the wild, the croaking gourami is mostly insectivorous, feeding on insects and insect larvae. However, other food types, such as zooplankton, crustaceans, shrimp meat and plant matter, are eaten as well. In aquaria, a varied diet is recommended: standard flake foods along with regular supplements of freeze-dried bloodworms, tubifex worms, brine shrimp, and some algae-based flakes will provide the fish with proper nutrition. Occasional feedings of live brine shrimp offer the aquarist an opportunity to observe the natural hunting behaviour of this species.
=== Drifting osteons === Drifting osteons are a phenomenon that is not fully understood. A "drifting osteon" is classified as one that runs both longitudinally as well as transversely through the cortex. An osteon can "drift" in one direction or change directions several times, leaving a tail of lamella behind the advancing haversian canal.
== Ownership and management == Jollibee is owned by the Jollibee Foods Corporation, which is based in Pasig, Philippines. JFC has operated as a franchisor since 1979. JFC also owns other fast food brands in the Philippines, including Chowking, Greenwich Pizza, Red Ribbon Bakeshop, and Mang Inasal, and it operates Burger King franchises.
The siege of Coimbra in 1064 or the definitive conquest of Coimbra by Christian forces took place in 1064, from January to July; it ended on 9 July 1064, a Friday, when the king, Ferdinand I of Leon, captured the city from the Muslims. The city of Coimbra had previously been taken from the Christians by Almanzor (or al-Manṣūr) in 987. When the Fitna of al-Andalus broke out and the Umayyad Caliphate of Cordova fragmented into numerous taifa states, Dom Sesnando Davides, lord of Tentúgal proposed the conquest of the city to Ferdinand of Leon. Ferdinand thus began preparations for the campaign in December 1063, after receiving the remains of Saint Isidore of Seville in León. Before he moved against Coimbra however, he made a pilgrimage to Santiago de Compostela. Having prayed there before the tomb of the apostle, St. James of Compostela, for three days and made several donations to the church there, he departed accompanied by his wife Dona Sancha, his sons, the Bishop Crescónio of Santiago, Bishop Vistruário of Lugo, Bishop Suário of Mondonhedo, Bishop Sesnando of Portugal, the abbot Ariano of Cela Nova, abbot Pedro of Guimarães, and a large number of nobles. They advanced through a coastal road that linked Santiago de Compostela to Iria Flavia to Braga, Porto and Coimbra. They arrived before the walls of the city on 20 January 1064. The Muslim garrison fiercely resisted the Christian attacks. The supply situation of the Christians was not favourable and Ferdinand even pondered lifting the siege.
=== Industrial production === Radon is obtained as a by-product of uraniferous ores processing after transferring into 1% solutions of hydrochloric or hydrobromic acids. The gas mixture extracted from the solutions contains H2, O2, He, Rn, CO2, H2O and hydrocarbons. The mixture is purified by passing it over copper at 993 K (720 °C; 1,328 °F) to remove the H2 and the O2, and then KOH and P2O5 are used to remove the acids and moisture by sorption. Radon is condensed by liquid nitrogen and purified from residue gases by sublimation. Radon commercialization is regulated, but it is available in small quantities for the calibration of 222Rn measurement systems. In 2008 it was priced at almost US$6,000 (equivalent to $8,972 in 2025) per milliliter of radium solution (which only contains about 15 picograms of actual radon at any given moment). Radon is produced commercially by a solution of radium-226 (half-life of 1,600 years). Radium-226 decays by alpha-particle emission, producing radon that collects over samples of radium-226 at a rate of about 1 mm3/day per gram of radium; equilibrium is quickly achieved and radon is produced in a steady flow, with an activity equal to that of the radium (50 Bq). Gaseous 222Rn (half-life of about four days) escapes from the capsule through diffusion. Radon sources have also been produced for scientific purposes through the implantation of radium-226 into solid stainless steel.
Sources: en.wikipedia.org
It corresponds to a fragment of the larger protein prothymosin alpha, which is present in many tissues. The isolated 28-amino-acid peptide was originally obtained from thymus preparations, and the pharmaceutical product is synthesized rather than extracted. The term therefore describes both a natural fragment and a manufactured drug substance.
Thymosin alpha-1 is a single defined 28-residue peptide, while the broader family includes unrelated peptides such as thymosin beta-4. The shared name reflects historical isolation from thymus tissue rather than a common structure. Confusion between the two is common in older literature.
No single pathway fully accounts for its reported effects. Several studies describe interaction with innate immune receptors and downstream cytokine changes, but the complete picture is not settled. Open questions remain about which effects occur at physiological concentrations.
Cool storage below freezing is usual for long-term retention, with a desiccant and protection from light. Portions are often split before first use to avoid repeated handling.